Defence Therapeutics Inc.
DTCFF
$0.6447
-$0.3517-35.30%
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 252.00K | 248.60K | 386.30K | 378.00K | 4.94M |
| Depreciation & Amortization | 12.70K | 13.00K | 35.50K | 16.70K | 5.10K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 421.90K | 354.20K | 857.90K | 870.80K | 6.09M |
| Operating Income | -421.90K | -354.20K | -857.90K | -870.80K | -6.09M |
| Income Before Tax | -575.00K | -444.90K | -985.30K | -984.80K | -6.12M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -575.00K | -444.90K | -985.30K | -984.80K | -6.12M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -575.00K | -444.90K | -985.30K | -984.80K | -6.12M |
| EBIT | -421.90K | -354.20K | -857.90K | -870.80K | -6.09M |
| EBITDA | -414.00K | -346.10K | -827.20K | -859.00K | -6.09M |
| EPS Basic | -0.01 | -0.01 | -0.02 | -0.02 | -0.14 |
| Normalized Basic EPS | -0.01 | -0.01 | -0.01 | -0.01 | -0.09 |
| EPS Diluted | -0.01 | -0.01 | -0.02 | -0.02 | -0.14 |
| Normalized Diluted EPS | -0.01 | -0.01 | -0.01 | -0.01 | -0.09 |
| Average Basic Shares Outstanding | 46.20M | 45.54M | 45.50M | 44.61M | 44.10M |
| Average Diluted Shares Outstanding | 46.20M | 45.54M | 45.50M | 44.61M | 44.10M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |